 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- |||| CAP-100 / Catapult Therap
Trial completion date, Trial primary completion date, Monotherapy: CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Feb 15, 2024
P=N/A, N=25, Recruiting, Sponsor: Catapult Therapeutics
Trial completion date: Sep 2023 --> Apr 2025 | Trial primary completion date: Sep 2023 --> Jan 2025
- | Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, CAP-100 / Catapult Therap
Journal: Evaluation of the novel therapeutic anti-CCR7 antibody CAP-100 as an add-on therapy in chronic lymphocytic leukemia patients receiving venetoclax. (Pubmed Central) - Dec 17, 2023
P=N/A
Our data indicate that venetoclax treatment did not significantly modify CCR7 expression pattern nor CAP-100 mechanisms of action. Together, these findings support CAP-100 as an adjuvant therapy to venetoclax that may introduce additional modes of action in CLL therapy.
- | CAP-100 / Catapult Therap
Journal: Effect of ibrutinib on CCR7 expression and functionality in chronic lymphocytic leukemia and its implication for the activity of CAP-100, a novel therapeutic anti-CCR7 antibody. (Pubmed Central) - Mar 1, 2022
P=N/A
Moreover, CLL cells are perfectly targetable by CAP-100 which led to a complete inhibition of CCR7-mediated migration and induced strong target cell killing through antibody-dependent cell-mediated cytotoxicity, irrespective of previous or contemporary ibrutinib administration. Together, these results validate the therapeutic utility of CAP-100 as a next-line single-agent therapy for CLL patients who failed to ibrutinib and confirm that CAP-100 and ibrutinib have complementary non-overlapping mechanisms of action, potentially allowing for combination therapy.
- | CAP-100 / Catapult Therap
Journal: Targeting cancer homing into the lymph node with a novel anti-CCR7 therapeutic antibody: the paradigm of CLL. (Pubmed Central) - Dec 30, 2021
P=N/A
Our results validated CAP-100 as a novel therapeutic tool to prevent the access of CLL cells, and other neoplasia with nodal-dependence, into the LN niches, thus hitting a central hub in the pathogenesis of cancer. The first-in-human clinical trial (NCT04704323), which will evaluate this novel therapeutic approach in CLL patients, is pending.
- ||| CAP-100 / Catapult Therap
Enrollment open, Trial initiation date, Trial primary completion date, Monotherapy: CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Sep 23, 2021
P=N/A, N=25, Recruiting, Sponsor: Catapult Therapeutics
The first-in-human clinical trial (NCT04704323), which will evaluate this novel therapeutic approach in CLL patients, is pending. Not yet recruiting --> Recruiting | Initiation date: Mar 2021 --> Sep 2021 | Trial primary completion date: Mar 2023 --> Sep 2023
- | CAP-100 / Catapult Therap
New trial, Monotherapy: CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Jan 10, 2021
P, N=22, Not yet recruiting, Sponsor: Catapult Therapeutics